NEW YORK (GenomeWeb) – Results from the Phase II SUMMIT trial, presented this weekend at the annual meeting of the American Association for Cancer Research in Washington, DC, have upheld the expectation that mutation status, regardless of tumor type or location, can contribute to response to targeted therapy.

The findings reiterate the importance of basket clinical trials that recruit patients not solely based on the location or clinical presentation of their tumor, but on the presence or absence of a particular mutation.